These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 10565855)

  • 21. A phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients.
    Pett SL; McCarthy MC; Cooper DA; MacRae K; Tendolkar A; Norris R; Strizki JM; Williams KM; Emery S
    Antivir Ther; 2009; 14(1):111-5. PubMed ID: 19320244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
    Seminari E; De Bona A; Gentilini G; Galli L; Schira G; Gianotti N; Uberti-Foppa C; Soldarini A; Dorigatti F; Lazzarin A; Castagna A
    J Antimicrob Chemother; 2007 Oct; 60(4):831-6. PubMed ID: 17684056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy.
    Günthard HF; Wong JK; Spina CA; Ignacio C; Kwok S; Christopherson C; Hwang J; Haubrich R; Havlir D; Richman DD
    J Infect Dis; 2000 Feb; 181(2):522-31. PubMed ID: 10669335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects.
    Goebel F; Yakovlev A; Pozniak AL; Vinogradova E; Boogaerts G; Hoetelmans R; de Béthune MP; Peeters M; Woodfall B
    AIDS; 2006 Aug; 20(13):1721-6. PubMed ID: 16931936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.
    Steel A; Cox AE; Shamji MH; John L; Nelson M; Henderson DC; Gotch FM; Gazzard BG; Kelleher P
    Antivir Ther; 2007; 12(6):971-5. PubMed ID: 17926652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement in immune parameters and human immunodeficiency virus-1 viral response in individuals treated with 16alpha-bromoepiandrosterone (HE2000).
    Reading C; Dowding C; Schramm B; Garsd A; Onizuka-Handa N; Stickney D; Frincke J
    Clin Microbiol Infect; 2006 Nov; 12(11):1082-8. PubMed ID: 17002607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332.
    Wade NA; Unadkat JD; Huang S; Shapiro DE; Mathias A; Yasin S; Ciupak G; Watts DH; Delke I; Rathore M; Hitti J; Frenkel L; Samelson R; Smith ME; Mofenson L; Burchett SK
    J Infect Dis; 2004 Dec; 190(12):2167-74. PubMed ID: 15551216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer.
    Cura JE; Blanzaco DP; Brisson C; Cura MA; Cabrol R; Larrateguy L; Mendez C; Sechi JC; Silveira JS; Theiller E; de Roodt AR; Vidal JC
    Clin Cancer Res; 2002 Apr; 8(4):1033-41. PubMed ID: 11948110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different patterns of HIV-1 DNA after therapy discontinuation.
    Re MC; Vitone F; Sighinolfi L; Schiavone P; Ghinelli F; Gibellini D
    BMC Infect Dis; 2005 Sep; 5():69. PubMed ID: 16156892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
    West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks.
    Paton NI; Aboulhab J
    HIV Med; 2005 Jan; 6(1):13-20. PubMed ID: 15670247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A pilot study of a combination of three reverse transcriptase inhibitors in HIV-1 infection.
    Lafeuillade A; Poggi C; Djediouane A; Chollet L; Profizi N; Sayada C
    Antivir Ther; 1997 Dec; 2(4):219-27. PubMed ID: 11327441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Large scale manufacturing of TXU(anti-CD7)-pokeweed antiviral protein (PAP) immunoconjugate for clinical trials.
    Myers DE; Jun X; Clementson D; Donelson R; Sicheneder A; Hoffman N; Bell K; Sarquis M; Langlie MC; Turner N; Uckun FM
    Leuk Lymphoma; 1997 Oct; 27(3-4):275-302. PubMed ID: 9402326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deguanylation of human immunodeficiency virus (HIV-1) RNA by recombinant pokeweed antiviral protein.
    Rajamohan F; Kurinov IV; Venkatachalam TK; Uckun FM
    Biochem Biophys Res Commun; 1999 Sep; 263(2):419-24. PubMed ID: 10491308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunoconjugates that neutralize HIV virions kill T cells infected with diverse strains of HIV-1.
    Kim YW; Fung MS; Sun NC; Sun CR; Chang NT; Chang TW
    J Immunol; 1990 Feb; 144(4):1257-62. PubMed ID: 2303707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and pharmacodynamics of subcutaneous interleukin-2 in HIV-infected patients.
    Piscitelli SC; Wells MJ; Metcalf JA; Baseler M; Stevens R; Davey RT
    Pharmacotherapy; 1996; 16(5):754-9. PubMed ID: 8888071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cationized hyperimmune immunoglobulins: pharmacokinetics, toxicity evaluation and treatment of human immunodeficiency virus-infected human-peripheral blood lymphocytes-severe combined immune deficiency mice.
    Pardridge WM; Kang YS; Diagne A; Zack JA
    J Pharmacol Exp Ther; 1996 Jan; 276(1):246-52. PubMed ID: 8558438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.